Stada and Xbrane eye global Lucentis target
Stada and Xbrane Biopharma have struck a co-development deal covering the Swedish firm’s Xlucane (ranibizumab) biosimilar, a proposed rival to Genentech’s Lucentis, with a worldwide scope.
You may also be interested in...
Sweden’s Xbrane BioPharma has followed through on plans to tap the equity markets for cash to fuel the planned launch of its Ximluci (ranibizumab) biosimilar version of Lucentis in Europe.
Bausch + Lomb has struck a deal for US and Canadian rights to the Xlucane ranibizumab biosimilar rival to Lucentis that is being developed by Xbrane Biopharma and Stada.
Through a partnership with Stada, Sweden’s Xbrane is looking to introduce a biosimilar to Lucentis in major developed markets, including the EU and the US, where the hunt for a commercialization partner continues.